ABBV vs PATH
AbbVie Inc (ABBV) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 305.0% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ABBV and PATH stock pages for the full models.
Not investment advice.